Best of 2025: Overview of the VEXAS Syndrome Save
Editor’s note: This article was originally published July 9, 2025, and shared as part of RheumNow's 'Best of 2025' series as we close out the year. Enjoy!
A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was discovered in 2020 and since, increasing reports have characterized this disorder. Al-Hakin et al. has reviewed the literature and included 720 patients from 33 case reports.
From this literature cohort, key clinical features included:
- cutaneous involvement (81.8%)
- constitutional symptoms (69.4%)
- respiratory disease (61.3%)
- Joint involvement (47.3%)
- Ocular disease (44.3%)
- Venous thromboembolism (41.8%)
VEXAS was complicated by myelodysplastic syndrome in 36%. There were also many under-recognised manifestations including significant respiratory and vascular complications.
Rare features included cardiac involvement (7.6%), renal disease (7.0%), and central nervous system manifestations (7.8%).
Better understanding of this novel entity will facilitate earlier diagnosis, better monitoring, and more effective therapies.
Continue Reading
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.